Key result
Arrhythmogenic right ventricular cardiomyopathy was associated with a 4.1% prevalence of intracardiac thrombosis, with female gender and left ventricular dysfunction as independent risk factors.
Why the study?
What is the prevalence, risk factors, and prognosis of intracardiac thrombosis in patients with ARVC, and does anticoagulation therapy improve outcomes?
Cohort (n=193)
What is the prevalence, risk factors, and prognosis of intracardiac thrombosis in patients with ARVC, and does anticoagulation therapy improve outcomes?
Intracardiac thrombosis occurs in approximately 4% of ARVC patients, particularly females with left ventricular dysfunction, and responds effectively to early anticoagulation therapy.
May warrant vigilance for thrombosis in female ARVC patients with LV dysfunction; leaves open anticoagulation benefit.
BACKGROUND: Intracardiac thrombus has been reported in anecdotal cases of arrhythmogenic right ventricular cardiomyopathy (ARVC). This prospective study aimed to determine the prevalence, risk factors, and prognosis of intracardiac thrombosis in patients with ARVC. METHODS: From February 2004 to August 2013, transthoracic echocardiograms and magnetic resonance imagings were performed in 193 patients with ARVC. The prevalence, risk factors, and prognosis of intracardiac thrombosis were investigated. RESULTS: Ten intracardiac thrombi were identified in 8 patients (4.1%), the majority (7/10) of which were found in the right ventricular apex. Multivariate analysis showed that female gender and left ventricular dysfunction were independently associated with increased risk for thrombosis in ARVC. All thrombi were eliminated in 3 weeks after anticoagulation therapy without any complication. During a median follow-up time of 38 months (range 2 to 128), no thromboembolism event or sudden death was observed in patients under anticoagulation therapy; however, in patients without anticoagulation therapy, definite pulmonary thromboembolism occurred in 1 and sudden death due to suspected pulmonary thromboembolism was observed in another. CONCLUSION: Intracardiac thrombosis may occur in certain patients with ARVC. Female gender and left ventricular dysfunction appeared to be associated with increased risk for thrombosis. Early screening and effective anticoagulation therapy may improve the prognosis.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2014) conducted a cohort in Arrhythmogenic right ventricular cardiomyopathy (n=193). Anticoagulation therapy vs. No anticoagulation therapy was evaluated on Prevalence of intracardiac thrombosis. Arrhythmogenic right ventricular cardiomyopathy was associated with a 4.1% prevalence of intracardiac thrombosis, with female gender and left ventricular dysfunction as independent risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: